A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Purpose Allergen-specific immunotherapy (SIT) requires dozens of subcutaneous injections over 3 to 5 years in order to control IgE-mediated hypersensitivity, which is a T-helper 2 (Th2)-associated pathology. This study investigates the use of poly(lactide-co-glycolide) (PLGA) microparticles combined with immunostimulatory oligodeoxynucleotide (CpG), as well as protamine in SIT.Materials and methods We prepared microparticle formulations with the major allergen of bee venom, phospholipase A2 (PLA2), and analyzed the effect of co-encapsulated or admixed CpG in both naïve and bee venom allergic mice.Results Mice immunized with microparticles containing only PLA2 induced weak antibody responses. In contrast, the combination with CpG resulted in strong PLA2-specific antibody responses. The presence of CpG was required for the induction of the Th1-associated isotype IgG2a, and the titers of IgG2a in sensitized mice correlated with a better protection against an allergen challenge. The effect of CpG was further strengthened when protamine was co-encapsulated for complexation of CpG.Conclusions This study shows that allergen-specific immunotherapy with a PLGA-based allergen-delivery system in combination with CpG enhanced the induction of protective IgG2a immune responses. This may improve SIT compliance and shorten its duration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“recent data indicated the counterbalance of Th2 responses by the use of PLGA particles co-encapsulated with the immuno stimulatory TLR9 ligand oligodeoxy-nucleotide (CpG), protamine and phospholipase A2 from bee venom [123].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [123]
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper
Bousquet, J., Lockey, R., & Malling, H.-J. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70271-4 · Cited by 1,581
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E.-M., Jacobson, M. R., O'Brien, F., Noble, W., Till, S. J., Hamid, Q. A., & Nouri-Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,373
Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases
Bousquet, J., Lockey, R., Malling, H. J., Alvarez-Cuesta, E., Canonica, G. W., Chapman, M. D., Creticos, P. J., Dayer, J. M., Durham, S. R., Demoly, P., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63136-5 · Cited by 736
Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity
Nouri-Aria, K. T., Wachholz, P. A., Francis, J. N., Jacobson, M. R., Walker, S. M., Wilcock, L. K., Staple, S. Q., Aalberse, R. C., Till, S. J., & Durham, S. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3252 · Cited by 564
Immunotherapy with a Ragweed–Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis
Creticos, P. S., Schroeder, J. T., Hamilton, R. G., Balcer-Whaley, S. L., Khattignavong, A. P., Lindblad, R., Li, H., Coffman, R., Seyfert, V., Eiden, J. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052916 · Cited by 562
Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.
Secrist, H., Chelen, C. J., Wen, Y., Marshall, J. D., & Umetsu, D. T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2123 · Cited by 539
In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes
Li, S., & Huang, L. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300482 · Cited by 475
Till, S. J., Francis, J. N., Nouri-Aria, K., & Durham, S. R. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.024 · Cited by 434
Durham, S. R., Ying, S., Varney, V. A., Jacobson, M. R., Sudderick, R. M., Mackay, I. S., Kay, A. B., & Hamid, Q. A. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70205-1 · Cited by 412
Nesterenko, M. V., Tilley, M., & Upton, S. J. (1994) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(94)90020-5 · Cited by 330
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Storni, T., Ruedl, C., Schwarz, K., Schwendener, R. A., Renner, W. A., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1777 · Cited by 286
Toll-like Receptors and Their Signaling Mechanisms
Akira, S., & Sato, S. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540310015683 · Cited by 265
Pharmacokinetics of Antisense Oligonucleotides
Agrawal, S., Temsamani, J., Galbraith, W., & Tang, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528010-00002 · Cited by 261
Double-blind placebo-controlled immunotherapy with mixed grass-pollen allergoids
Bousquet, J., Maasch, H., Martinot, B., Hejjaoui, A., Wahl, R., & Michel, F. B. (1988) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(88)90017-6 · Cited by 203
GEHLHAR, SCHLAAK, BECKER, & BUFE (1999) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1999.00525.x · Cited by 167
Phosphorothioate Backbone Modification Modulates Macrophage Activation by CpG DNA
Sester, D. P., Naik, S. H., Beasley, S. J., Hume, D. A., & Stacey, K. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4165 · Cited by 135
Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids
Bousquet, J. J., Hejjaoui, A., Soussana, M., & Michel, F. B. (1990) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(90)90160-6 · Cited by 133
A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy
Kussebi, F., Karamloo, F., Rhyner, C., Schmid‐Grendelmeier, P., Salagianni, M. L., Mannhart, C., Akdiş, M., Soldatova, L., Marković-Housley, Z., von Beust, B. R., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.041 · Cited by 94
Self-citationLee, S. W., Song, M., Baek, K. H., Park, Y., Kim, J. K., Lee, C. H., Cheong, H., Cheong, C., & Sung, Y. C. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3631 · Cited by 73
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Farman, C. A., & Kornbrust, D. J. (2003) · Toxicologic Pathology · doi:10.1080/01926230309779 · Cited by 70
Toll‐like receptor ligands as adjuvants in allergen‐specific immunotherapy
Johansen, P., Senti, G., Martinez Gomez, J. M., Storni, T., von Beust, B. R., Wüthrich, B., Bot, A., & Kündig, T. M. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02384.x · Cited by 57
Self-citationFreitas, S., Walz, A., Merkle, H. P., & Gander, B. (2003) · Journal of Microencapsulation · doi:10.1080/02652040210162577 · Cited by 57
Self-citationFischer, S., Foerg, C., Ellenberger, S., Merkle, H. P., & Gander, B. A. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.015 · Cited by 52
Self-citationHeat denaturation, a simple method to improve the immunotherapeutic potential of allergens
Johansen, P., Senti, G., Martínez Gómez, J. M., Wüthrich, B., Bot, A., & Kündig, T. M. (2005) · European Journal of Immunology · doi:10.1002/eji.200535076 · Cited by 51
Self-citationBanerjee, B., Kelly, K. J., Fink, J. N., Henderson, J. D., Bansal, N. K., & Kurup, V. P. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6087-6094.2004 · Cited by 51
Design, engineering and in vitro evaluation of MHC class‐II targeting allergy vaccines
Crameri, R., Flückiger, S., Daigle, I., Kündig, T. M., & Rhyner, C. (2007) · Allergy · doi:10.1111/j.1398-9995.2006.01292.x · Cited by 47
Self-citationBiodegradable microspheres containing group B Streptococcus vaccine: Immune response in mice
Hunter, S. K., Andracki, M. E., & Krieg, A. Μ. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.117658 · Cited by 42
Gebrekidan, S., Woo, B. H., & DeLuca, P. P. (2000) · AAPS PharmSciTech · doi:10.1208/pt010428 · Cited by 42
Immunological adjuvants in allergy vaccines: Past, present future
Wheeler, A. W., & Woroniecki, S. R. (2001) · Allergology International · doi:10.1046/j.1440-1592.2001.00230.x · Cited by 41
Jilek, S., Walter, E., Merkle, H. P., & Corthésy, B. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.05.065 · Cited by 39
Self-citationPark, Y., Chang, Y., Lee, S. W., Cho, S. Y., Kim, Y., Min, K., Kim, Y. Y., Cho, S., & Sung, Y. C. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118517 · Cited by 38
Kim, M., Lee, J.-W., Yook, H., Lee, S., Kim, M., & Byun, M. (2002) · Journal of Food Protection · doi:10.4315/0362-028x-65.7.1192 · Cited by 37
Peyre, M., Sesardic, D., Merkle, H. P., Gander, B., & Johansen, P. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10361 · Cited by 36
Self-citationWild, C., Wallner, M., Hufnagl, K., Fuchs, H., Hoffmann‐Sommergruber, K., Breiteneder, H., Scheiner, O., Ferreira, F., & Wiedermann, U. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01245.x · Cited by 32
Peyre, M., Audran, R., Estevez, F., Corradin, G., Gander, B. A., Sesardic, D., & Johansen, P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.014 · Cited by 24
Self-citationFerreiro, M. G. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00140-6 · Cited by 21
Peptide-based Vaccines in the Treatment of Specific Allergy
Alexander, C. E., Kay, A. B., & Larché, M. (2002) · Current Drug Targets - Inflammation & Allergy · doi:10.2174/1568010023344562 · Cited by 17
Anti‐T‐cell strategies in the treatment of allergic disease
Larché, M. (2002) · Allergy · doi:10.1034/j.1398-9995.57.s72.9.x · Cited by 8
Cited by
Silva, A. L., Soema, P. C., Slütter, B., Ossendorp, F., & Jiskoot, W. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1117714 · Cited by 251
Peptide/protein vaccine delivery system based on PLGA particles
Allahyari, M., & Mohit, E. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102804 · Cited by 232
Mohanan, D., Slütter, B., Henriksen-Lacey, M., Jiskoot, W., Bouwstra, J. A., Perrie, Y., Kündig, T. M., Gander, B., & Johansen, P. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.012 · Cited by 229
Self-citationSilva, J. M., Zupančič, E., Vandermeulen, G., Oliveira, V. G., Salgado, A., Videira, M., Gaspar, M. M., Graça, L., Préat, V., & Florindo, H. F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.033 · Cited by 160
Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles
Hamdy, S. I., Haddadi, A., Shayeganpour, A., Samuel, J., & Lavasanifar, A. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0459-9 · Cited by 126
Metadata
- Authors
- Gómez, J. M. M., Fischer, S., Csaba, N., Kündig, T. M., Merkle, H. P., Gander, B., & Johansen, P.
- Affiliations
- University Hospital Zurich (CH)
- ETH Zurich (CH)
- Corresponding author
- Johansen, Pål
- Venue
- Pharmaceutical Research
- Published
- 2007-05-31
- Volume
- 24
- Issue
- 10
- Pages
- 1927-1935
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2045281155
- Cited by
- 63
- References
- 44
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 4 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.zora.uzh.ch
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- ETH Zürich Research Collection
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- allergen immunotherapy, allergy vaccines, PLGA microspheres, CpG oligodeoxynucleotides, protamine, bee venom allergy, phospholipase A2, IgG2a, Th1 response, IgE-mediated hypersensitivity
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Adjuvants, Immunologic, Allergens, Anaphylaxis, Animals, Bee Venoms, Chemistry, Pharmaceutical, Desensitization, Immunologic, Disease Models, Animal, Drug Carriers, Drug Compounding, Hypersensitivity, Immunoglobulin E, Immunoglobulin G, Injections, Subcutaneous, Oligodeoxyribonucleotides, Particle Size, Polyglycolic Acid, Polymers, Protamines, Time Factors, Vaccines, Th1 Cells, Lactic Acid, Mice, Phospholipases A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.